| Primary |
| Heparin Neutralisation Therapy |
50.6% |
| Surgery |
10.3% |
| Cardiac Operation |
8.0% |
| Product Used For Unknown Indication |
5.7% |
| Coagulopathy |
3.4% |
| Drug Use For Unknown Indication |
2.3% |
| Haemostasis |
2.3% |
| Heparin Resistance |
2.3% |
| Procoagulant Therapy |
2.3% |
| Afib |
1.1% |
| Anticoagulant Therapy |
1.1% |
| Cardiovascular Disorder |
1.1% |
| Carotid Artery Occlusion |
1.1% |
| Carotid Endarterectomy |
1.1% |
| Coagulation Time Prolonged |
1.1% |
| Coronary Artery Surgery |
1.1% |
| Endarterectomy |
1.1% |
| Fistula Repair |
1.1% |
| Haemorrhage |
1.1% |
| Prothrombin Time Prolonged |
1.1% |
|
| Hypotension |
32.4% |
| Pulmonary Hypertension |
10.3% |
| Procedural Hypotension |
5.9% |
| Urticaria |
5.9% |
| Cardiac Arrest |
4.4% |
| Cardio-respiratory Arrest |
4.4% |
| Procedural Complication |
4.4% |
| Anaphylactic Reaction |
2.9% |
| Drug Hypersensitivity |
2.9% |
| Hypersensitivity |
2.9% |
| Nausea |
2.9% |
| No Therapeutic Response |
2.9% |
| Respiratory Distress |
2.9% |
| Right Ventricular Dysfunction |
2.9% |
| Transfusion-related Acute Lung Injury |
2.9% |
| Ventricular Tachycardia |
2.9% |
| Anaphylactic Shock |
1.5% |
| Angioedema |
1.5% |
| Blood Pressure Systolic Decreased |
1.5% |
| Bronchospasm |
1.5% |
|
| Secondary |
| Drug Use For Unknown Indication |
38.2% |
| Product Used For Unknown Indication |
17.8% |
| Heparin Neutralisation Therapy |
7.6% |
| Anticoagulant Therapy |
4.9% |
| Blood Pressure Increased |
4.1% |
| Electrolyte Substitution Therapy |
3.6% |
| Haemorrhage Prophylaxis |
3.6% |
| Hypotension |
3.0% |
| Anaesthesia |
2.5% |
| Coronary Artery Bypass |
2.4% |
| Aortic Valve Replacement |
2.2% |
| Antiphospholipid Syndrome |
1.7% |
| Coagulation Time Abnormal |
1.5% |
| Cardiac Disorder |
1.0% |
| Catheterisation Cardiac |
1.0% |
| Coagulopathy |
1.0% |
| Heart Valve Operation |
1.0% |
| Hypertension |
1.0% |
| Thrombosis Prophylaxis |
1.0% |
| Aortic Dissection |
0.8% |
|
| Grand Mal Convulsion |
26.9% |
| Ventricular Hypokinesia |
7.7% |
| Convulsion |
5.1% |
| Intracardiac Thrombus |
5.1% |
| Product Measured Potency Issue |
5.1% |
| Ventricular Tachycardia |
5.1% |
| Cardiac Arrest |
3.8% |
| Fear |
3.8% |
| Premature Baby |
3.8% |
| Premature Rupture Of Membranes |
3.8% |
| Product Quality Issue |
3.8% |
| Right Ventricular Failure |
3.8% |
| Thrombocytopenia |
3.8% |
| Anhedonia |
2.6% |
| Haemorrhage |
2.6% |
| Heart Rate Decreased |
2.6% |
| Maternal Exposure During Pregnancy |
2.6% |
| Procedural Complication |
2.6% |
| Pulmonary Thrombosis |
2.6% |
| Pyrexia |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
60.0% |
| Coronary Artery Bypass |
11.5% |
| Drug Use For Unknown Indication |
9.5% |
| Aortic Valve Replacement |
3.7% |
| Catheterisation Cardiac |
2.8% |
| Mitral Valve Replacement |
2.1% |
| Hypertension |
1.5% |
| Mitral Valve Repair |
1.5% |
| Cardiac Operation |
1.1% |
| Pain |
1.0% |
| Multiple Myeloma |
0.8% |
| Tricuspid Valve Repair |
0.7% |
| Cardiopulmonary Bypass |
0.7% |
| Anticoagulant Therapy |
0.5% |
| Aortic Surgery |
0.5% |
| Anxiety |
0.5% |
| Cardiac Ablation |
0.5% |
| Prophylaxis |
0.4% |
| Diabetes Mellitus |
0.4% |
| Gastrooesophageal Reflux Disease |
0.4% |
|
| Injury |
14.5% |
| Pain |
13.3% |
| Unevaluable Event |
10.6% |
| Fear |
8.5% |
| Anxiety |
8.1% |
| Renal Failure |
6.9% |
| Anhedonia |
6.7% |
| Emotional Distress |
6.2% |
| Stress |
4.2% |
| Renal Injury |
3.5% |
| Depression |
3.4% |
| Renal Impairment |
3.2% |
| Multi-organ Failure |
2.2% |
| Death |
2.0% |
| Renal Failure Acute |
1.9% |
| Cerebrovascular Accident |
1.5% |
| Nervousness |
0.9% |
| Disability |
0.8% |
| Fear Of Death |
0.8% |
| Respiratory Failure |
0.7% |
|
